Big pharma, biotech relations ‘won't necessarily be symbiotic’ in future AI landscape: S&P

Big Pharma is investing heavily in AI to slash development timelines and foster innovation. But instead of strengthening future relationships with the biotech world, the investment may position independent AI-focused biotechs as a threat to pharma’s internal R&D processes.